DE2530862C2 - Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus - Google Patents

Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus

Info

Publication number
DE2530862C2
DE2530862C2 DE2530862A DE2530862A DE2530862C2 DE 2530862 C2 DE2530862 C2 DE 2530862C2 DE 2530862 A DE2530862 A DE 2530862A DE 2530862 A DE2530862 A DE 2530862A DE 2530862 C2 DE2530862 C2 DE 2530862C2
Authority
DE
Germany
Prior art keywords
alcoholism
dlphosphate
treatment
prevention
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2530862A
Other languages
German (de)
English (en)
Other versions
DE2530862A1 (de
Inventor
Shun-ichi Yokohama Kanagawa Hata
Etsuko Tokio/Tokyo Mitsuishi
Koji Tokorozawa Saitama Mizuno
Yasuho Niiza Saitama Nishii
Motoharu Ohmiya Saitama Shiba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE2530862A1 publication Critical patent/DE2530862A1/de
Application granted granted Critical
Publication of DE2530862C2 publication Critical patent/DE2530862C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C07H5/10—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2530862A 1974-07-11 1975-07-10 Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus Expired DE2530862C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7873274 1974-07-11

Publications (2)

Publication Number Publication Date
DE2530862A1 DE2530862A1 (de) 1976-01-29
DE2530862C2 true DE2530862C2 (de) 1984-12-06

Family

ID=13670046

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2530862A Expired DE2530862C2 (de) 1974-07-11 1975-07-10 Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus

Country Status (4)

Country Link
US (1) US4058601A (Direct)
DE (1) DE2530862C2 (Direct)
FR (1) FR2277591A1 (Direct)
GB (1) GB1512043A (Direct)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2037289B (en) * 1978-10-31 1983-05-05 Katsunuma N Nucleoside derivatives and an antileukemial agent containing the same as an active ingredient
US5597810A (en) 1984-12-27 1997-01-28 Hoffman; Allan S. Method for reducing absorption of undesired lipids in the gastrointestinal tract
FI82483C (fi) * 1986-12-03 1991-03-11 Inst Biolog Morya Dalnevostoch Foerfarande foer framstaellning av en alkoholdryck.
US4808574A (en) * 1986-12-03 1989-02-28 Nauchno-Issledovatelsky Institut Sadovodstva Composition inhibiting pathological addiction to alcohol
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
IT1219919B (it) * 1988-04-11 1990-05-24 Foscama Biomed Chim Farma Impiego del fruttosio-1,6-difosfato nel trattamento della intossicazione alcolica acuta e dell' etilismo cronico e composizioni farmaceutiche relative
CA2016709A1 (en) * 1989-05-15 1990-11-15 University Of Cincinnati Stable aqueous solution having high concentrations of calcium and phosphate ions and solid complex
WO1996001115A1 (en) * 1994-07-01 1996-01-18 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CA2300146A1 (en) * 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4260M (Direct) * 1964-11-18 1966-07-04
US3852435A (en) * 1972-10-30 1974-12-03 Yamasa Shoyu Kk Uridine-5{40 -diphosphate-glucuronic acid compositions
US3852433A (en) * 1973-04-06 1974-12-03 Yamasa Shoyu Kk Uridine-5-monophosphate compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS-ERMITTELT

Also Published As

Publication number Publication date
GB1512043A (en) 1978-05-24
US4058601A (en) 1977-11-15
FR2277591B1 (Direct) 1979-06-08
FR2277591A1 (fr) 1976-02-06
DE2530862A1 (de) 1976-01-29

Similar Documents

Publication Publication Date Title
DE3586545T2 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
CH653891A5 (de) Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier.
DE69219136T2 (de) Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
EP0857064B1 (de) Stabilisierte schilddrüsenhormonhaltige arzneimittel
DE3137125C2 (Direct)
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
DE2530862C2 (de) Verwendung von Uridin-5'-diphosphat zur Verhütung und Behandlung von Alkoholismus
DE3343934A1 (de) M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
DE69829290T2 (de) Verwendung von alkanoylcarnitinderivaten zur behandlung von hyperaktivität mit aufmerksamkeitsstörungen
EP0224810B1 (de) Antihypertensives Kombinationspräparat
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
CH677612A5 (Direct)
DE69835609T2 (de) L-valine für lebererkrankungen
DE3875107T2 (de) Verwendung von fructose-1,6-diphosphat zur behandlung von akuten alkoholvergiftungen und chronischem alkoholismus und verwandte pharmazeutische zusammensetzungen.
DE69525348T2 (de) Medikament gegen myotonische dystrophie
DE3301328A1 (de) Arzneimittel zur einleitenden bekaempfung von akuter oder chronischer, myelogener leukaemie
DE69115102T2 (de) Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren.
DE2525064C2 (de) Arzneimittel mit Antiparkinson-Wirkung
DE2743704C2 (de) L- oder DL-Phenylglycine enthaltende Arzneimittel
DE2528460A1 (de) Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
DE2728589B2 (de) Verwendung von 2-(2,2-disubstituierten)-ÄthylimidazoIinen bei der Bekämpfung von Diabetes
DE2314387C3 (de) Arzneimittel zur Behandlung bösartiger Neubildungen
DE3714322C2 (de) Prophylaktisches und therapeutisches Mittel für hepatische Krankheiten

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee